Royalty Pharma Financing Receivables increased by 1.5% to $17.32B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $15.75B to $17.32B. Over 5 years (FY 2020 to FY 2025), Financing Receivables shows an upward trend with a 5.7% CAGR.
Growth generally signals expansion of the lending business, while a decline may indicate contraction or a shift in capital allocation strategy.
Financing receivables represent the aggregate contractual amounts due from customers arising from lending and leasing ac...
Standard metric across all commercial and retail banking institutions.
financing_receivables| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.53B | $14.59B | $14.33B | $14.04B | $14.06B | $14.96B | $14.18B | $14.27B | $14.00B | $13.97B | $14.83B | $14.13B | $14.64B | $15.73B | $15.91B | $15.75B | $15.98B | $16.62B | $17.06B | $17.32B |
| QoQ Change | — | +7.9% | -1.8% | -2.1% | +0.2% | +6.4% | -5.2% | +0.6% | -1.9% | -0.2% | +6.1% | -4.7% | +3.6% | +7.5% | +1.1% | -1.0% | +1.5% | +4.0% | +2.6% | +1.5% |
| YoY Change | — | — | — | — | +3.9% | +2.5% | -1.0% | +1.7% | -0.5% | -6.6% | +4.5% | -1.0% | +4.6% | +12.6% | +7.3% | +11.5% | +9.1% | +5.7% | +7.2% | +10.0% |